David Lund, Ph.D., is the Vice President, Intellectual Property at Neogene Therapeutics. Before coming to Neogene, Dr. Lund served most recently as Senior IP Counsel at Agenus, where his responsibilities included managing IP issues for Agenus’ affiliate AgenTus in addition to early stage and near-commercial antibody programs of Agenus. Prior to that, Dr. Lund was the John F. Witherspoon Legal Fellow at the Center for the Protection of Intellectual Property at George Mason University, Antonin Scalia Law School. There Dr. Lund was involved in governmental and public advocacy in support of a well-functioning patent system. Dr. Lund began his legal career as an associate at Dechert LLP, where his work focused on counseling large biopharmaceutical companies on a wide range of intellectual property issues and assisting venture capital firms in overseeing IP issues related to their portfolio companies.
Dr. Lund received his J.D. and undergraduate degrees from the University of Michigan. He received his Ph.D. from Vanderbilt University working in the lab of Dr. Randy Blakely where he studied mechanisms to enhance choline transporter function as a possible path to the treatment of myasthenia gravis or Alzheimer’s Disease. He is a member of the bar in California and registered to practice before the United States Patent and Trademark Office.
